科研动态期刊摘要
[评论] Deucrictibant：一种用于遗传性血管性水肿的新型口服按需治疗药物
The Lancet · 2026-10-23 21:12
摘要
由C1抑制剂缺乏所致的遗传性血管性水肿（HAE-C1INH）在临床上以复发性、通常不可预测的血管性水肿发作为特征。1未治疗的发作往往严重且持续时间长，可持续3–5天，并导致相当高的发病率甚至死亡率。2与肥大细胞介质相关的血管性水肿不同，HAE-C1INH的肿胀对抗组胺药、糖皮质激素或肾上腺素均无反应。
English
[Comment] Deucrictibant: a novel oral on-demand treatment for hereditary angioedema
Hereditary angioedema due to a deficiency of C1 inhibitor (HAE-C1INH) is clinically characterised by recurrent, generally unpredictable attacks of angioedema.1 Untreated episodes are often severe and prolonged, lasting up to 3–5 days and engendering considerable morbidity and even mortality.2 Unlike angioedema associated with mast cell mediators, the swelling in HAE-C1INH does not respond to antihistamines, corticosteroids, or epinephrine.